0000000000015165

AUTHOR

Lourdes Bondanza

showing 7 related works from this author

Diálisis peritoneal en pericarditis constrictiva: a propósito de 3 casos

2017

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industry030232 urology & nephrologymedicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología
researchProduct

Carbohydrate Antigen-125–Guided Therapy in Acute Heart Failure

2016

Abstract Objectives This study sought to evaluate the prognostic effect of carbohydrate antigen-125 (CA125)–guided therapy (CA125 strategy) versus standard of care (SOC) after a hospitalization for acute heart failure (AHF). Background CA125 has emerged as a surrogate of fluid overload and inflammatory status in AHF. After an episode of AHF admission, elevated values of this marker at baseline as well as its longitudinal profile relate to adverse outcomes, making it a potential tool for treatment guiding. Methods In a prospective multicenter randomized trial, 380 patients discharged for AHF and high CA125 were randomly assigned to the CA125 strategy (n = 187) or SOC (n = 193). The aim in th…

medicine.medical_specialtyendocrine system diseasesbusiness.industry030204 cardiovascular system & hematologymedicine.diseaseRate ratiofemale genital diseases and pregnancy complicationslaw.inventionClinical trial03 medical and health sciences0302 clinical medicineRandomized controlled triallawHeart failureInternal medicineAmbulatoryCardiovascular agentmedicineClinical endpoint030212 general & internal medicineCardiology and Cardiovascular MedicineIntensive care medicinebusinessCause of deathJACC: Heart Failure
researchProduct

Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

2017

Abstract Introduction and objectives The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1. Methods Multicenter, open-label, parallel clinical trial, in which patients with AHF and serum creatinine ≥ 1.4 mg/dL on admission will be randomized to: a) standard diuretic str…

medicine.medical_specialtymedicine.medical_treatmentWater-Electrolyte ImbalanceRenal functionCardiorenal syndrome030204 cardiovascular system & hematologyPatient Care Planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFurosemideInternal medicineHumansMedicine030212 general & internal medicineDiureticsIntensive care medicineHeart FailureCreatinineCardio-Renal Syndromebusiness.industryClinical study designChlorthalidoneMembrane ProteinsGeneral Medicinemedicine.diseasePathophysiologyAcetazolamideClinical trialchemistryCA-125 AntigenCreatinineHeart failureAcute DiseaseCardiologyDiureticbusinessRevista Española de Cardiología (English Edition)
researchProduct

Differential Effect of Glycosylated Hemoglobin Value and Antidiabetic Treatment on the Risk of 30-day Readmission Following a Hospitalization for Acu…

2015

In patients with heart failure and type 2 diabetes, low glycosylated hemoglobin has been related with higher risk of mortality but information regarding morbidity is scarce. We sought to evaluate the association between glycosylated hemoglobin and 30-day readmission in patients with type 2 diabetes and acute heart failure.Glycosylated hemoglobin was measured before discharge in 835 consecutive patients with acute heart failure and type 2 diabetes. Cox regression analysis adapted for competing events was used.Mean (standard deviation) age was 72.9 (9.6) years and median glycosylated hemoglobin was 7.2% (6.5%-8.0%). Patients treated with insulin or insulin/sulfonylurea/meglitinides were 41.1%…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentType 2 diabetesGastroenterologyPatient ReadmissionRisk AssessmentInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsAgedRetrospective StudiesGlycated HemoglobinHeart FailureProportional hazards modelbusiness.industryInsulinHazard ratioGeneral Medicinemedicine.diseasePrognosisSulfonylureaConfidence intervalPatient DischargeSurvival RateEndocrinologyDiabetes Mellitus Type 2SpainHeart failureAcute DiseaseFemalebusinessFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Estrategias diuréticas en insuficiencia cardiaca aguda con disfunción renal: terapia convencional frente a guiada por el antígeno carbohidrato 125. D…

2017

Resumen Introduccion y objetivos El tratamiento optimo de pacientes con insuficiencia cardiaca aguda (ICA) y sindrome cardiorrenal tipo 1 (SCR-1) no esta bien definido. La hipoperfusion arterial y la congestion venosa tienen un papel fundamental en la fisiopatologia del SCR-1. El antigeno carbohidrato 125 (CA125) ha emergido como marcador indirecto de sobrecarga de volumen en la ICA. El objetivo de este estudio es evaluar la utilidad del CA125 para el ajuste del tratamiento diuretico de pacientes con SCR-1. Metodos Ensayo clinico multicentrico, abierto y paralelo, que incluye a pacientes con ICA y creatinina ≥ 1,4 mg/dl al ingreso, aleatorizados a: a)  estrategia convencional: titulacion ba…

03 medical and health sciences0302 clinical medicinebusiness.industryMedicine030212 general & internal medicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

Peritoneal Dialysis in Constrictive Pericarditis: A Report of Three Cases

2017

Constrictive pericarditismedicine.medical_specialtybusiness.industrymedicine.medical_treatment030232 urology & nephrologyGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseSurgeryPeritoneal dialysis03 medical and health sciences0302 clinical medicinemedicinebusinessRevista Española de Cardiología (English Edition)
researchProduct

Efecto diferencial de la glucohemoglobina y el tratamiento antidiabético sobre el riesgo de reingreso a 30 días después de un ingreso por insuficienc…

2015

Introduccion y objetivos En los pacientes con insuficiencia cardiaca y diabetes tipo 2, las cifras bajas de glucohemoglobina se han relacionado con un riesgo mas elevado de mortalidad, pero la informacion relativa a la morbilidad es escasa. El objetivo de este estudio fue evaluar la asociacion existente entre la glucohemoglobina y el reingreso en un plazo de 30 dias en los pacientes con diabetes tipo 2 e insuficiencia cardiaca aguda. Metodos Se determino la glucohemoglobina antes del alta en 835 pacientes consecutivos con insuficiencia cardiaca aguda y diabetes tipo 2. Se utilizo un analisis de regresion de Cox adaptado para eventos competitivos. Resultados La media de edad fue de 72,9 ± 9,…

business.industryMedicineCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct